Czech and Slovak Ophthalmology 71 10.31348/2018/1/3-2-2018 Original article Result of the first 12 months of treatment of macular edema complicating brvo in patients treated with ranibizumab Lalinská Lucia Krásný Jan https://orcid.org/0000-0002-0341-0094 Studený Pavel https://orcid.org/0000-0003-1279-4074 Veith Miroslav https://orcid.org/0000-0001-6254-436X 23 8 2018 2 3

The aim of the study: Retrospective evaluation of the first 12 months treatment of macular edema in BRVO with ranibizumab based on anatomical and functional parameters. Methods: 54 eyes with macular edema complicating BRVO were included in the study, with an average initial best corrected visual acuity 4/16 ETDRS charts, an average central retinal thickness 512.3 μm, and in average 4 months till the beginning of treatment with ranibizumab. After 3 initial injections of 0.5 mg ranibizumab treatment was performed in pro re nata regimen, with adjuvant laser (grid laser photocoagulation) as an additional treatment option. The number of injections administered, the number of eyes where grid laser photocoagulation was provided, functional parameters as a letter gain and BCVA (eyes with final BCVA ≥ 4/8 ETDRS, final BCVA in according to initial BCVA) and anatomical parameters as a mean CRT and CRT ≤ 250 μm, respectively ≤ 300 μm were evaluated. Results: In the whole group, an average of 4.8 injections of ranibizumab were administered in the first 12 months. Grid laser photocoagulation was performed in 42 eyes: in 8 eyes prior to the beginning of treatment with ranibizumab, 7 eyes before and during the treatment, 29 eyes only during the treatment. The main gain of letters after 12 months of treatment was +16.5 letters, with 63¨% (n = 34) eyes earning ≥ 15 letters. In the whole group 72 % (n = 39) eyes achieved the resulting BCVA ≥ 4/8 ETDRS after 12 months of treatment. The eyes with initial BCVA ≥ 4/10 ETDRS resulted in BCVA ≥ 4/8 ETDRS in 96 % (n = 23 eyes) and 11 eyes even achieved BCVA ≥ 4/4. The mean CRT after 12 months of treatment was 290.3 μm, 33.3 % of eyes had final CRT ≤ 250 μm, and 64.8 % had final CRT ≤ 300 μm. Conclusion: When applying a relatively low number of injections in the first year of treatment with ranibizumab, the final best corrected visual acuity was very good at the end of the observation period, and its dependence on the initial best corrected visual acuity was confirmed. Satisfactory results of central retinal thickness were found as well.

 branch retinal vein occlusion macular edema ranibizumab References Bringmann, A., Reichenbach, A., Wiedeman, P.: Pathomechanism of cystoid macular edema. Ophtalmic Res, 36; 2004: 241-249. Brown, DM., Campochiaro, PA., Bhisitkul, RB., et al.: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophtalmology, 118; 2011: 1594-1602. Brynskov, T., Kemp, H., Sørensen, TL.: Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice. Retina, 34; 2014: 1637-1643 Duker, JS., Brown, GC.: Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophtalmol, 107; 1989: 998-1000. Gutman, FA., Zegarra, H., Zakov, ZN.: The natural course of temporal retinal vein. Trans Am Acad Ophtalmol Otola- Exp Ophthalmol, 249; 2011: 183-192. Hayreh, SS., Zimmermann, B., McCarthy, MJ., et al.: Systemic diseases associated with various types of retinal vein occlusion. Amer J Ophthalmol, 131; 2001: 61-77. Cheung, N., Klein, R., Wang, JJ., et al.: Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci, 49; 2008: 4297-4302. Christoffersen, NLB., Larsen, M.: Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology, 106; 1999: 2054-2062. Jaissle, GB., Szurman, P., Feltgen, N.: Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.Graefes Arch Clin Michels, RG., Gass, JD.: The natural course of temporal retinal branch vein obstruction. Trans Am Acad Ophtalmol Otolaryngol, 79; 1974: 166-177. Noma, H., Funatsu, H., Yamasaki, M., et al.: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin 6. Am J Ophtalmol, 140; 2005: 256-261. O’Mahoney, DT., Wong, T., Ray, JG.: Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol, 126; 2008: 692-699. Osinbowale, O., Ali, L., Chi, YW.: Ve - nous trombembolism: a clinical review. Postgrad Med, 122; 2010: 54-65. Rehák, M., Krčová, V.: Poruchy hematokoagulační kaskády. In Řehák, J., Rehák, M., et al., Venózní okluze sítnice. Praha, Trends Ophtalmol, 12; 1997: 41-45. Rezar, S., Eibenberger, K., Bühl, W., et al.: Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophtal, 93; 2015: 719–725. Rogers, S., McIntosh, RL., Cheung, N., et al.: International Eye Consortium: The prevalence of retinal vein occlusion: pooled data from population studies from United States, Europe, Asia, and Australia. Ophtalmology, 117; 2010: 313-319. Řehák, J.: Branch retinal vein occlusion: Part 1. Pathogenesis, collaterals and visual prognosis. New approach. New Řehák, J.: Venózní okluze sítnice: I. Příspěvek k patogenezi cirkulačních změn. Českoslov. Oftalmol, 49; 1993: 145-147. Řehák, J., Dušek, L., Chrapek, O. et al.: Initial visual acuity is an important prognostic factor in patients with branch retinal vein occlusion. Ophtalmic Research 45; 2011: 204-209. Řehák, J., Rehák, M.: Fotokoagulační te - rapie okluze větve sítnicové vény. In Řehák, J., Rehák, M., et al., Venózní okluze sítnice. Praha, Grada, 2011, 89-93. Šín, M.: Optická koherenční tomografie. InŘehák, J., Rehak, M., et al., Venózní okluze sítnice. Praha, Grada, 2011, 74-75. Grada, 2011, 49-54. Vinores, SA., Youssri, AI., Luna, JD.: Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol., 12; 1997: 99-109. Wong, TY., Larsen, EK., Klein, R., et al.: Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology, 112; 2005: 540–547. Zhao, J., Sastry, SM., Sperduto, RD., et al.: Arteriovenous crossing patterns in branch retinal vein occlusion. Ophtalmology, 100; 1993: 423-428.